In a January 2017 article, veterinary cardiologist Mikaela Mueller commented on this observation: "Patients in the pimobendan group did not live as long as the placebo group after the onset of congestive heart failure, but overall survival time (all-cause mortality) was increased." Oddly, the EPIC Study researchers have not included this information in their article, but that missing data raises the question of whether the shortened life span of CHF dogs treated with pimobendan during Stage B2 is due either to drug toxicity or to an acquired pharmacological tolerance to the pimobendan

Live Now All times eastern NOW - 12:00 AM 12:00 AM 12:30 AM 1:00 AM 1:30 AM 2:00 AM Fox Business Channel How America Works 11:00 PM - 12:00 AM How America Works 12:00 AM - 1:00 AM Paid Programming 1:00 AM - 1:30 AM Paid Programming 1:30 AM - 2:00 AM Paid Programming 2:00 AM - 2:30 AM Fox News Channel Fox News @ Night 11:00 PM - 12:00 AM The Five 12:00 AM - 1:00 AM Jesse Watters Primetime 1:00 AM - 2:00 AM Hannity 2:00 AM - 2:30 AM Fox Weather Channel Fox Weather Live Stream Fox News Radio FOX News Radio Live Channel Coverage Live Stream
These were placebo injections
You should also ask whether anything in your medical history amounts to a contraindication, or even constitutes a potential concern
Several commenters cited examples of persistent disparities in care, including maternal mortality rates across the population and differences between urban and rural health outcomes
Clinical data on sex-specific differences in mood side effects from GLP-1 therapy are still emerging